Eisai Co. and Merck received approval from the FDA for the combination of Eisai’s LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor, plus Merck’s KEYTRUDA, an anti-PD-1 therapy, for the treatment of advanced endometrial carcinoma that’s not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy.   The approval is based on results from a Phase 3 Study in which LENVIMA plus KEYTRUDA demonst...